{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T03:56:27Z","timestamp":1793073387166,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002095","name":"Food Allergy and Anaphylaxis Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015516","name":"Revance Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.parkreldis.2025.108015","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:16:29Z","timestamp":1756826189000},"page":"108015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials"],"prefix":"10.1016","volume":"140","author":[{"given":"Aaron","family":"Ellenbogen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Xingyue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-2578","authenticated-orcid":false,"given":"Jin","family":"Lingjing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5482-5313","authenticated-orcid":false,"given":"Todd M.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3223-2597","authenticated-orcid":false,"given":"Rashid","family":"Kazerooni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5488-6594","authenticated-orcid":false,"given":"Conor J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Xiaojing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Xinhua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.parkreldis.2025.108015_bib1","article-title":"Dystonia","volume":"4","author":"Balint","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.parkreldis.2025.108015_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-325193","article-title":"Quality of life in isolated dystonia: non-motor manifestations matter","author":"Junker","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108015_bib3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00415-020-10378-5","article-title":"Head tremor and pain in cervical dystonia","volume":"268","author":"Vu","year":"2021","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.parkreldis.2025.108015_bib4","article-title":"Botulinum toxin type A therapy for cervical dystonia","volume":"11","author":"Rodrigues","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"issue":"19","key":"10.1016\/j.parkreldis.2025.108015_bib5","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American academy of neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108015_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12050332","article-title":"FDA approvals and consensus guidelines for botulinum toxins in the treatment of dystonia","volume":"12","author":"Spiegel","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108015_bib7","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00415-020-10217-7","article-title":"Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia","volume":"268","author":"Comella","year":"2021","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.parkreldis.2025.108015_bib8","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00702-013-1048-3","article-title":"A randomized, double-blind study of repeated IncobotulinumtoxinA (Xeomin\u00ae) in cervical dystonia","volume":"120","author":"Evidente","year":"2013","journal-title":"J. Neural Transm."},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108015_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3111\/13696998.2011.653726","article-title":"Satisfaction with botulinum toxin treatment: a cross-sectional survey of patients with cervical dystonia","volume":"15","author":"Sethi","year":"2012","journal-title":"J. Med. Econ."},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108015_bib11","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/17425247.2023.2251399","article-title":"A technology evaluation of the atypical use of a CPP-containing peptide in the formulation and performance of a clinical botulinum toxin product","volume":"20","author":"Dowdy","year":"2023","journal-title":"Expet Opin. Drug Deliv."},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.108015_bib12","article-title":"A cell penetrating peptide enhances membrane binding of botulinum neurotoxin type A and increases SNAP-25 cleavage","volume":"237","author":"Batista","year":"2024","journal-title":"Toxicon"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.108015_bib13","article-title":"A cell-penetrating peptide binds directly to and enhances membrane binding of the core toxin of botulinum toxin type A (BoNTA)","volume":"214","author":"Pulkoski-Gross","year":"2022","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.parkreldis.2025.108015_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.toxicon.2011.05.012","article-title":"Characterization of diffusion and duration of action of a new botulinum toxin type A formulation","volume":"58","author":"Stone","year":"2011","journal-title":"Toxicon"},{"issue":"Suppl 1","key":"10.1016\/j.parkreldis.2025.108015_bib15","article-title":"Novel peptide excipient RTP004 enhances the binding of botulinum neurotoxin type A cell binding domain HC to rat brain synaptosomes","volume":"156","author":"Weisemann","year":"2018","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108015_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208091","article-title":"Efficacy and safety of DaxibotulinumtoxinA for injection in cervical dystonia: ASPEN-1 phase 3 randomized controlled trial","volume":"102","author":"Comella","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2025.108015_bib20","author":"Neurosciences"},{"issue":"9","key":"10.1016\/j.parkreldis.2025.108015_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.parkreldis.2025.108015_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-na\u00efve patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2025.108015_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.parkreldis.2025.108015_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hed.2880120504","article-title":"Botulinum A toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread","volume":"12","author":"Borodic","year":"1990","journal-title":"Head Neck"},{"issue":"10","key":"10.1016\/j.parkreldis.2025.108015_bib26","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/toxins16100442","article-title":"Dysphagia and muscle weakness secondary to botulinum toxin type A treatment of cervical dystonia: a drug class analysis of prescribing information","volume":"16","author":"Dashtipour","year":"2024","journal-title":"Toxins"},{"issue":"3","key":"10.1016\/j.parkreldis.2025.108015_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mdc3.12613","article-title":"Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study","volume":"5","author":"Jankovic","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.parkreldis.2025.108015_bib28","series-title":"Real-World Early Experience With DaxibotulinumtoxinA in Adults With Cervical Dystonia","author":"McAllister","year":"2024"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025007564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802025007564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:44:35Z","timestamp":1772883875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802025007564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S1353802025007564"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108015","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of DaxibotulinumtoxinA for injection in adults with cervical dystonia: Pooled global analysis of ASPEN-1 and ASPEN-1-CN randomized trials","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2025.108015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Revance, TN, USA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108015"}}